Recently, the phase 3 PACIFIC trial demonstrated the durable benefits of durvalumab, an inhibitor of programmed death-ligand 1 (PD-L1), on overall survival (OS) of patients with unresectable stage III NSCLC [2,3]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.